Dymista – could be the drug of choice

The renowned Journal of Allergy and Clinical Immunology ((JACI;2012;129:1282–9)
published an article on the clinical development program for Dymista (project
code MP29-02), Meda’s novel intranasal therapy for allergic rhinitis (AR). The
authors summarize the results of three clinical studies in a meta-analysis
including 3,398 patients. They show that Dymista treats all symptoms more
effectively than the currently recommended first-line therapies.

A new study from Bousquet et al. to be presented at EAACI in Geneva, Switzerland
(June 16-20 2012), revealed that up to 90% of AR patients take many types of
clinically untested medication combinations to achieve better symptom control.
“Efficacy at any stage of the disease is very important for AR patients, and
Dymista fulfils this need since it is, to date, the most effective therapy
regardless of disease severity. Dymista represents a significant advance in AR
management and will transform how this disease is managed, comparable to the
innovation seen with asthma management in the past decade”, said Prof. Jean
Bousquet, Professor of pulmonary medicine, University of Montpellier, France,
founder and Chairman of the Allergic Rhinitis and its Impact on Asthma (ARIA)
guidelines and one of the authors of the article.

Dymista offers rapid and more complete symptom relief. Patients treated with
Dymista achieve a clinically-relevant symptom reduction up to 5 days earlier
than standard AR therapy. “Using a single fast-acting product for symptom
control should appeal to patients, improving compliance and reducing costs” said
the lead author Dr. Warner Carr. The concept of complete/almost complete
response, introduced by Dr. Carr, shows that Dymista “could effectively ‘cure’
up to 60 million AR sufferers around the globe”.

Notably, the Editorial of the Journal shared the article’s conclusion that
Dymista can be considered the drug of choice for AR therapy because it offers
additional benefits to patients with AR, in particular those with moderate-to
-severe AR.

About Allergic Rhinitis

AR is a world-wide epidemic that currently affects more than 500 million people
around the world. It represents a global health problem that causes major
illness and disability. The effects of AR are not fully recognized and are still
underestimated (e.g. AR has more negative effects that affect a patient’s
quality of life, school and work performance than asthma). The frequency of AR
is rising, with the majority of patients suffering from moderate-to-severe AR,
which is frequently poorly controlled. Dymista currently represents the most
effective therapy for these patients.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR      ph: +46 709
-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under Large Cap
on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit
www.meda.se.

Forward-looking statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.